|
|
 |
|
| |
Cell Genesys' diversified business assets provide multiple opportunities to create shareholder value. In addition to multiple clinical stage product development programs, the company remains a minority owner of Ceregene, Inc., a Cell Genesys former subsidiary focused on gene therapies for neurologic disorders. Furthermore, Cell Genesys owns an extensive technology and patent estate.
With a GMP manufacturing facility, Cell Genesys believes it is well positioned to manufacture product for multiple Phase 3 clinical trials and potential commercial launch.
|
|
|
